Envestnet Asset Management
PTGX icon

Envestnet Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Envestnet Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.35M Buy
19,134
+2,817
+17% +$294K ﹤0.01% 3038
2026
Q1 		$1.72M Buy
16,317
+1,644
+11% +$146K ﹤0.01% 3112
2025
Q4 		$1.28M Sell
14,673
-9,585
-40% -$785K ﹤0.01% 3131
2025
Q3 		$1.61M Buy
24,258
+380
+2% +$21.6K ﹤0.01% 3020
2025
Q2 		$1.32M Buy
23,878
+7,199
+43% +$346K ﹤0.01% 3098
2025
Q1 		$807K Buy
16,679
+7,698
+86% +$323K ﹤0.01% 3339
2024
Q4 		$347K Sell
8,981
-3,802
-30% -$166K ﹤0.01% 3813
2024
Q3 		$575K Sell
12,783
-776
-6% -$31.4K ﹤0.01% 3468
2024
Q2 		$470K Buy
13,559
+2,390
+21% +$70K ﹤0.01% 3494
2024
Q1 		$323K Buy
+11,169
New +$304K ﹤0.01% 3686

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Envestnet Asset Management's PTGX Position: Q2 2026 in Review

Envestnet Asset Management increased its Protagonist Therapeutics (PTGX) stake by 17% in Q2 2026, buying an estimated $294K and bringing the position to 19,134 shares worth $2.35M. The position accounts for ﹤0.01% of the portfolio, ranked #3038.

Envestnet Asset Management first reported a position in PTGX in Q1 2024 and has held it in 10 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Envestnet Asset Management held 19,134 shares of Protagonist Therapeutics worth $2.35M as of Q2 2026.
  • Envestnet Asset Management bought 2,817 Protagonist Therapeutics shares in Q2 2026, an estimated $294K.
  • Protagonist Therapeutics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #3038 holding.
  • Envestnet Asset Management first reported a position in Protagonist Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.